Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucagon Infusion Tolerability in Obese Subjects
NCT02817659Phase 1Active, not recruiting
- Sponsor
- AdventHealth Translational Research Institute
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glucagon in obesity, sponsored by AdventHealth Translational Research Institute. Primary endpoint: Glucagon tolerance prior to significant nausea at 60 months. Started Nov 2016; status: active, not recruiting.
02
Drugs
glucagon
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02817659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817659.